Combination Foretinib and Anti-PD-1 Antibody Immunotherapy for Colorectal Carcinoma

Combination Foretinib and Anti-PD-1 Antibody Immunotherapy for Colorectal Carcinoma

Immune checkpoint inhibitors have achieved unprecedented success in cancer immunotherapy. However, the overall response rate to immune checkpoint inhibitor therapy for many cancers is only between 20 and 40%, and even less for colorectal cancer (CRC) patients. Thus, there is an urgent need to develo...

Full description

Bibliographic Details
Main Authors:	Yuyin Fu, Yujia Peng, Shengyan Zhao, Jun Mou, Lishi Zeng, Xiaohua Jiang, Chengli Yang, Cheng Huang, Yuyan Li, Yin Lu, Mengdan Wu, Yanfang Yang, Ting Kong, Qinhuai Lai, Yangping Wu, Yuqin Yao, Yuxi Wang, Lantu Gou, Jinliang Yang
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2021-07-01
Series:	Frontiers in Cell and Developmental Biology
Subjects:	foretinib anti-PD-1 combination therapy immunotherapy tumor microenvironment colon cancer
Online Access:	https://www.frontiersin.org/articles/10.3389/fcell.2021.689727/full

Similar Items

Investigation of the Impact of Foretinib on AURKA and AURKB Expression in T98 Glioblastoma Cell Line
by: Mansour Moghimi, et al.
Published: (2019-02-01)

Effect of Foretinib on Matrix Metalloproteinase-2 (MMP2) Expression in Glioblastoma
by: Maryam Fotoohi, et al.
Published: (2018-12-01)

Foretinib Inhibits Cancer Stemness and Gastric Cancer Cell Proliferation by Decreasing CD44 and c-MET Signaling
by: Sohn SH, et al.
Published: (2020-02-01)

Combination of Selected MET and EGFR Inhibitors Decreases Melanoma Cells’ Invasive Abilities
by: Aleksandra Simiczyjew, et al.
Published: (2019-10-01)

Characterization of Melanoma Cell Lines Resistant to Vemurafenib and Evaluation of Their Responsiveness to EGFR- and MET-Inhibitor Treatment
by: Ewelina Dratkiewicz, et al.
Published: (2019-12-01)

Targeting of DDR1 with antibody‐drug conjugates has antitumor effects in a mouse model of colon carcinoma
by: Yiran Tao, et al.
Published: (2019-09-01)

Einfluss von HGF und Foretinib auf den Glukosestoffwechsel bei Zelllinien des oralen Plattenepithelkarzinoms
by: Abt, Alexander
Published: (2020)

UPLC–MS/MS assay for quantification of an inhibitor of kinases (Foretinib) in plasma: Application to a pharmacokinetic study in rats
by: Essam Ezzeldin, et al.
Published: (2020-04-01)

Combination of EGFR Inhibitor Lapatinib and MET Inhibitor Foretinib Inhibits Migration of Triple Negative Breast Cancer Cell Lines
by: Aleksandra Simiczyjew, et al.
Published: (2018-09-01)

Phase II study evaluating 2 dosing schedules of oral foretinib (GSK1363089), cMET/VEGFR2 inhibitor, in patients with metastatic gastric cancer.
by: Manish A Shah, et al.
Published: (2013-01-01)

Application of PD-1 Blockade in Cancer Immunotherapy
by: Xiaomo Wu, et al.
Published: (2019-01-01)

Comparative RNA-sequencing profiled the differential gene expression of liver in response to acetyl-CoA carboxylase inhibitor GS-0976 in a mouse model of NASH
by: Ying Lu, et al.
Published: (2019-12-01)

Multidimensional Analyses of Tumor Immune Microenvironment Reveal the Possible Rationality of Immunotherapy and Identify High Immunotherapy Response Subtypes for Renal Papillary Cell Carcinoma
by: Baojun Wei, et al.
Published: (2021-08-01)

Polymorphisms in CISH gene are associated with persistent hepatitis B virus infection in Han Chinese population.
by: Zhangyong Hu, et al.
Published: (2014-01-01)

β-Arrestin1 mediates the endocytosis and functions of macrophage migration inhibitory factor.
by: Lishi Xie, et al.
Published: (2011-01-01)

A phase-I study of lapatinib in combination with foretinib, a c-MET, AXL and vascular endothelial growth factor receptor inhibitor, in human epidermal growth factor receptor 2 (HER-2)-positive metastatic breast cancer
by: Stephen K. Chia, et al.
Published: (2017-05-01)

PD-1/PD-L blockade in gastrointestinal cancers: lessons learned and the road toward precision immunotherapy
by: Junyu Long, et al.
Published: (2017-08-01)

Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma
by: Xin Wang, et al.
Published: (2019-02-01)

LSD1 silencing contributes to enhanced efficacy of anti-CD47/PD-L1 immunotherapy in cervical cancer
by: Shengjie Xu, et al.
Published: (2021-03-01)

Perspective of Immunopathogenesis and Immunotherapies for Kawasaki Disease
by: Lung Chang, et al.
Published: (2021-07-01)

PD-1/PD-L1 Checkpoint Inhibitors in Tumor Immunotherapy
by: Jinhua Liu, et al.
Published: (2021-09-01)

New developments in immunotherapy for lymphoma
by: Benjamin Heyman, et al.
Published: (2018-09-01)

Mechanism of microtubule stabilization by taccalonolide AJ
by: Yuxi Wang, et al.
Published: (2017-06-01)

Activatable polymer nanoagonist for second near-infrared photothermal immunotherapy of cancer
by: Yuyan Jiang, et al.
Published: (2021-02-01)

Gastroenterological Cancer and Immunotherapy
by: Xiaoping Wang, et al.
Published: (2018-01-01)

Anti-PD-1 Immunotherapy and Bee Venom for Relapsed and Refractory Liposarcoma: A Case Report
by: Wei Yang, et al.
Published: (2021-04-01)

Identifikasi Sesar Bawah Permukaan Dengan Menggunakan Metoda Geolistrik Konfigurasi Wenner Di Sekitar Das Jene’berang, Kecamatan Parangloe, Kabupaten Gowa, Sulawesi Selatan
by: Syamsuddin, Lantu, Muh. Altin Massinai Syaeful Akbar, et al.
Published: (2012-12-01)

Mechanisms and Clinical Trials of Hepatocellular Carcinoma Immunotherapy
by: Shao-Li Huang, et al.
Published: (2021-07-01)

Aristolochic Acid and Immunotherapy for Urothelial Carcinoma: Directions for unmet Needs
by: Huang-Yu Yang, et al.
Published: (2019-06-01)

Mesoporous Silica Nanoparticles for Potential Immunotherapy of Hepatocellular Carcinoma
by: Han Wu, et al.
Published: (2021-10-01)

Tumor Immune Microenvironment Characterization Identifies Prognosis and Immunotherapy-Related Gene Signatures in Melanoma
by: Dan Liu, et al.
Published: (2021-05-01)

Immune contexture defined by single cell technology for prognosis prediction and immunotherapy guidance in cancer
by: Tong Wu, et al.
Published: (2019-04-01)

A review on the advances and challenges of immunotherapy for head and neck cancer
by: Gang Cheng, et al.
Published: (2021-07-01)

Research Progress of PD-1/PD-L1 Targeted Radionuclide Molecular Probes in Tumor Immunotherapy
by: WANG Shujing, et al.
Published: (2020-01-01)

Immunotherapy for Lung Cancers
by: Ming-Yi Ho, et al.
Published: (2011-01-01)

Immunotherapy for Lung Cancer: Mechanisms of Resistance and Response Strategy
by: Yaning YANG, et al.
Published: (2021-02-01)

Immunotherapy is expected to be the ultimate nemesis of malignant glioma
by: Xue⁃jun YANG
Published: (2020-02-01)

BCMA-Targeting Therapy: Driving a New Era of Immunotherapy in Multiple Myeloma
by: Shih-Feng Cho, et al.
Published: (2020-06-01)

Evolution of Lung Cancer in the Context of Immunotherapy
by: Sheng Yu, et al.
Published: (2020-12-01)

Adipose PD-L1 Modulates PD-1/PD-L1 Checkpoint Blockade Immunotherapy Efficacy in Breast Cancer
by: Bogang Wu, et al.
Published: (2018-11-01)

Cannot write session to /tmp/vufind_sessions/sess_vrm8ltrk1nrj117d4n0emjmvab